Latest Sciclone Pharmaceuticals (SCLN) Headlines
Post# of 43
Posted On: 03/13/2014 1:42:36 PM
Latest Sciclone Pharmaceuticals (SCLN) Headlines
SciClone Reports 2013 Financial Results and 2014 Outlook
Marketwire - Wed Mar 12, 5:01AM CDT
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported financial results for the fourth quarter and year ended December 31, 2013.
SciClone Pharmaceuticals to Report Financial Results for the Fourth Quarter and Full Year 2013 on March 12th
Marketwire - Mon Mar 03, 5:00AM CST
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it plans to report financial results for the fourth quarter and full year 2013 on Wednesday, March 12, 2014. SciClone will host a conference call and webcast to provide a business and product update at 8:30 am ET that day. The call will be hosted by Friedhelm Blobel, Ph.D., President and CEO, and Wilson W. Cheung, Senior Vice President and CFO.
10-K: DISCOVER FINANCIAL SERVICES
Edgar Online - Tue Feb 25, 5:06AM CST
Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations
SciClone Pharmaceuticals Inc names Charles Meng as VP of Compliance
M2 - Mon Feb 10, 10:15AM CST
Pharmaceutical company SciClone Pharmaceuticals Inc (NASDAQ:SCLN) revealed on Monday the appointment of Charles Meng as general counsel and vice president of its Compliance.
SciClone Appoints Charles Meng as General Counsel and Vice President of Compliance
Marketwire - Mon Feb 10, 5:00AM CST
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced the appointment of Charles Meng as General Counsel and Vice President of Compliance effective February 9, 2014. Mr. Meng has more than 20 years of experience in compliance and legal affairs spanning multinational companies in diverse industries, including pharmaceuticals, high technology and electronics, as well as in academia and government service. Mr. Meng will report to Friedhelm Blobel, Ph.D., Chief Executive Officer, and will be based in SciClone's Shanghai headquarters.
Spectre of Smuggling and Nigeria's Rice Business
by Crusoe Osagie - All Africa Global Media - Tue Feb 04, 8:52AM CST
With an annual N360 billion (about $2 billion) at stake in the Nigerian rice business, smuggling would certainly be a difficult battle to fight in the country. The problem is even more intractable as it appears to subtly enjoy the support of national government in countries sharing borders with Nigeria, including Benin, Cameroon and Niger.
SciClone to Present at BIO CEO & Investor Conference on February 11, 2014
Marketwire - Mon Feb 03, 5:00AM CST
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Friedhelm Blobel, Ph.D., Chief Executive Officer, will present a corporate overview and business update at the 16th Annual BIO CEO & Investor Conference at 10:00 am ET on Tuesday, February 11, 2014, at the Waldorf Astoria Hotel in New York City.
ManpowerGroup Reports 4th Quarter and Full Year 2013 Results
PR Newswire - Thu Jan 30, 6:30AM CST
ManpowerGroup (NYSE: MAN) today reported net earnings of $1.25 per diluted share for the three months ended December 31, 2013 compared to 68 cents per diluted share in the prior period. The net earnings in the quarter were $101.2 million compared to $53.3 million a year earlier. Revenues for the fourth quarter totaled $5.3 billion, an increase of 1 percent from the year earlier period in U.S. dollars and constant currency.
Nasdaq stocks posting largest percentage increases
AP - Tue Jan 28, 5:03PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Harwood Feffer LLP Announces Investigation of SciClone Pharmaceuticals, Inc.
PR Newswire - Mon Jan 27, 9:15PM CST
NEW YORK, Jan. 27, 2014 /PRNewswire/-- Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of SciClone Pharmaceuticals, Inc. ("SciClone" or the "Company") (NASDAQ: SCLN), concerning whether the board has breached its fiduciary duties to shareholders.
Bronstein, Gewirtz & Grossman, LLC Announces Investigation of SciClone Pharmaceuticals, Inc.
PR Newswire - Mon Jan 27, 3:30PM CST
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of SciClone Pharmaceuticals, Inc. ("SciClone" or the "Company") (NasdaqGS: SCLN). Such investors are advised to contact Peretz Bronstein or his investor Relation's coordinator Eitan Kimelman at info@bgandg.com or 212-697-6484.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors SciClone Pharmaceuticals, Inc.
PR Newswire - Mon Jan 27, 9:08AM CST
Pomerantz LLP is investigating claims on behalf of investors of SciClone Pharmaceuticals, Inc. ("SCLN" or the "Company") (NASDAQ: SCLN) Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 237.
SciClone Announces Transition From Pricewaterhousecoopers LLP to Pricewaterhousecoopers Zhong Tian LLP as Independent Registered Public Accounting Firm
Marketwire - Fri Jan 24, 5:30PM CST
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that the Audit Committee of the Company's Board of Directors has appointed PricewaterhouseCoopers Zhong Tian LLP ("PwC China") to replace PricewaterhouseCoopers LLP ("PwC US") as the Company's independent registered public accounting firm, effective January 24, 2014. The transition of the audit engagement from PwC US to PwC China was based on the determination that PwC China is the principal auditor under applicable auditing standards and on a variety of quantitative and qualitative factors related to the business, including the geographic location of assets, revenues and operations of the Company.
Global and Chinese Synthesis Polypeptide Drug Industry Report 2014
M2 - Mon Jan 20, 2:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/k4ccf3/global_and) has announced the addition of the "Global and Chinese Synthesis Polypeptide Drug Industry Report 2014" report to their offering. The Global and Chinese Synthesis Polypeptide Drug Industry Report 2014 is a professional and in-depth study on the current state of the global polypeptide drug industry with a focus on the Chinese situation. It is a valuable source of guidance and direction for companies and individuals interested in the market. The report provides a basic overview of the industry including definitions, classifications, applications, professional team interpretation and industry chain structure. Polypeptide drug market analysis is provided for both the international and Chinese domestic situations including development trends, competitive landscape analysis, key regions development status and a comparison analysis between the international and Chinese markets. Development policies and plans are also discussed and manufacturing processes and cost structures analyzed. Polypeptide drug industry import/export consumption, supply and demand figures and cost price and production value gross margins are also provided. A key feature of the report is its focus on 20 industry players providing information such as products, customers, application, capacity, market position, company contact information and summary statistics. Upstream raw materials and equipment and downstream demand analysis is also carried out. Polypeptide drug industry development trends and marketing channels are analyzed. Finally the feasibility of new investment projects are assessed and overall research conclusions offered. Key Topics Covered - Synthesis Polypeptide Drug Industry Overview - Synthesis Polypeptide Drug International and China Market Analysis - Major Synthesis Polypeptide Drug Analysis - Synthesis Polypeptide Drug Industry Development Environmental Analysis - Synthesis Polypeptide Drug Development Policy and Plan - Synthesis Polypeptide Drug Manufacturing Process and Cost Structure - 2009-2014 Synthesis Polypeptide Drug Productions Supply Sales Demand Market Status and Forecast - Synthesis Polypeptide Drug Key Manufacturers - Up and Down Stream Industry Analysis and Influence - Synthesis Polypeptide Drug Marketing Channels Analysis - Synthesis Polypeptide Drug Industry Development Proposals - Synthesis Polypeptide Drug New Project Investment Feasibility Analysis - Synthesis Polypeptide Drug Industry Research Conclusions Companies Mentioned - Asahi Kasei - AstraZeneca - Beijing Shuanglu Pharmaceutical - Beijing Yingu Century Pharmaceutical (Beijing Shiqiao Bio-Pharmaceutical) - Changzhou Siyao Pharmaceutical - Chengdu Tiantaishan Pharmaceutical - Ferring Pharmaceuticals - HYBIO Pharmaceutical - Hainan Shuangcheng Pharmaceuticals - Hainan Zhonghe Pharmaceutical - Ipsen PHarma Biotech - Lilly - Livzon Pharmaceuticals - Merck Serono - Novartis - SciClone Pharmaceuticals - Sichuan Chengdu Diao Pharmaceutical Group - Takeda - Wuhan Hualong Bio-Chemical Pharmaceutical - Yangzijiang Pharmaceutica For more information visit http://www.researchandmarkets.com/research/k4ccf3/global_and About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Don Kan Filling Station Rejects Government's 'Cheaters' Label
by Henry Karmo - All Africa Global Media - Wed Jan 15, 9:31AM CST
The management of Don Kan Filling Station in Liberia has described as false and misleading, unfounded in a sharp response to the cheater label by the Ministry of Commerce against the company. Don Kan in a statement, also accused the Ministry of Commerce of witch hunting.
4 Stocks Under $10 Moving Higher
at The Street - Wed Jan 15, 6:00AM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
IPVanish VPN Partners With Lag Assassin -- Game Online With Assassin Speed
GlobeNewswire - Tue Jan 14, 8:43AM CST
IPVanish VPN, the world's leading provider of premium, high-performance VPN service, is thrilled to announce its latest partnership with exciting new service - Lag Assassin. Lag Assassin is powered by the Highwinds Game Delivery Network (GDN) and is new on the market as of just last week! While IPVanish secures Internet traffic, Lag Assassin gives online gamers a competitive edge with better ping time no matter what game they're playing. It does this by avoiding the unnecessary traffic paths an ISP takes while running in the background during game play.
SciClone Provides 2013 Financial Update and 2014 Guidance
Marketwire - Thu Jan 09, 5:00AM CST
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced its anticipated year-end 2013 cash position and provided its initial 2014 revenue guidance as follows.
SciClone to Present at Oppenheimer Healthcare Conference on December 10, 2013
Marketwire - Mon Dec 02, 5:00AM CST
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Friedhelm Blobel, Ph.D., Chief Executive Officer, will present a corporate overview and business update at the Oppenheimer 24th Annual Healthcare Conference on Tuesday, December 10, 2013, at 3:20 pm ET at the Crowne Plaza Hotel in New York.
SciClone Reports 2013 Financial Results and 2014 Outlook
Marketwire - Wed Mar 12, 5:01AM CDT
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported financial results for the fourth quarter and year ended December 31, 2013.
SciClone Pharmaceuticals to Report Financial Results for the Fourth Quarter and Full Year 2013 on March 12th
Marketwire - Mon Mar 03, 5:00AM CST
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it plans to report financial results for the fourth quarter and full year 2013 on Wednesday, March 12, 2014. SciClone will host a conference call and webcast to provide a business and product update at 8:30 am ET that day. The call will be hosted by Friedhelm Blobel, Ph.D., President and CEO, and Wilson W. Cheung, Senior Vice President and CFO.
10-K: DISCOVER FINANCIAL SERVICES
Edgar Online - Tue Feb 25, 5:06AM CST
Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations
SciClone Pharmaceuticals Inc names Charles Meng as VP of Compliance
M2 - Mon Feb 10, 10:15AM CST
Pharmaceutical company SciClone Pharmaceuticals Inc (NASDAQ:SCLN) revealed on Monday the appointment of Charles Meng as general counsel and vice president of its Compliance.
SciClone Appoints Charles Meng as General Counsel and Vice President of Compliance
Marketwire - Mon Feb 10, 5:00AM CST
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced the appointment of Charles Meng as General Counsel and Vice President of Compliance effective February 9, 2014. Mr. Meng has more than 20 years of experience in compliance and legal affairs spanning multinational companies in diverse industries, including pharmaceuticals, high technology and electronics, as well as in academia and government service. Mr. Meng will report to Friedhelm Blobel, Ph.D., Chief Executive Officer, and will be based in SciClone's Shanghai headquarters.
Spectre of Smuggling and Nigeria's Rice Business
by Crusoe Osagie - All Africa Global Media - Tue Feb 04, 8:52AM CST
With an annual N360 billion (about $2 billion) at stake in the Nigerian rice business, smuggling would certainly be a difficult battle to fight in the country. The problem is even more intractable as it appears to subtly enjoy the support of national government in countries sharing borders with Nigeria, including Benin, Cameroon and Niger.
SciClone to Present at BIO CEO & Investor Conference on February 11, 2014
Marketwire - Mon Feb 03, 5:00AM CST
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Friedhelm Blobel, Ph.D., Chief Executive Officer, will present a corporate overview and business update at the 16th Annual BIO CEO & Investor Conference at 10:00 am ET on Tuesday, February 11, 2014, at the Waldorf Astoria Hotel in New York City.
ManpowerGroup Reports 4th Quarter and Full Year 2013 Results
PR Newswire - Thu Jan 30, 6:30AM CST
ManpowerGroup (NYSE: MAN) today reported net earnings of $1.25 per diluted share for the three months ended December 31, 2013 compared to 68 cents per diluted share in the prior period. The net earnings in the quarter were $101.2 million compared to $53.3 million a year earlier. Revenues for the fourth quarter totaled $5.3 billion, an increase of 1 percent from the year earlier period in U.S. dollars and constant currency.
Nasdaq stocks posting largest percentage increases
AP - Tue Jan 28, 5:03PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Harwood Feffer LLP Announces Investigation of SciClone Pharmaceuticals, Inc.
PR Newswire - Mon Jan 27, 9:15PM CST
NEW YORK, Jan. 27, 2014 /PRNewswire/-- Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of SciClone Pharmaceuticals, Inc. ("SciClone" or the "Company") (NASDAQ: SCLN), concerning whether the board has breached its fiduciary duties to shareholders.
Bronstein, Gewirtz & Grossman, LLC Announces Investigation of SciClone Pharmaceuticals, Inc.
PR Newswire - Mon Jan 27, 3:30PM CST
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of SciClone Pharmaceuticals, Inc. ("SciClone" or the "Company") (NasdaqGS: SCLN). Such investors are advised to contact Peretz Bronstein or his investor Relation's coordinator Eitan Kimelman at info@bgandg.com or 212-697-6484.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors SciClone Pharmaceuticals, Inc.
PR Newswire - Mon Jan 27, 9:08AM CST
Pomerantz LLP is investigating claims on behalf of investors of SciClone Pharmaceuticals, Inc. ("SCLN" or the "Company") (NASDAQ: SCLN) Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 237.
SciClone Announces Transition From Pricewaterhousecoopers LLP to Pricewaterhousecoopers Zhong Tian LLP as Independent Registered Public Accounting Firm
Marketwire - Fri Jan 24, 5:30PM CST
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that the Audit Committee of the Company's Board of Directors has appointed PricewaterhouseCoopers Zhong Tian LLP ("PwC China") to replace PricewaterhouseCoopers LLP ("PwC US") as the Company's independent registered public accounting firm, effective January 24, 2014. The transition of the audit engagement from PwC US to PwC China was based on the determination that PwC China is the principal auditor under applicable auditing standards and on a variety of quantitative and qualitative factors related to the business, including the geographic location of assets, revenues and operations of the Company.
Global and Chinese Synthesis Polypeptide Drug Industry Report 2014
M2 - Mon Jan 20, 2:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/k4ccf3/global_and) has announced the addition of the "Global and Chinese Synthesis Polypeptide Drug Industry Report 2014" report to their offering. The Global and Chinese Synthesis Polypeptide Drug Industry Report 2014 is a professional and in-depth study on the current state of the global polypeptide drug industry with a focus on the Chinese situation. It is a valuable source of guidance and direction for companies and individuals interested in the market. The report provides a basic overview of the industry including definitions, classifications, applications, professional team interpretation and industry chain structure. Polypeptide drug market analysis is provided for both the international and Chinese domestic situations including development trends, competitive landscape analysis, key regions development status and a comparison analysis between the international and Chinese markets. Development policies and plans are also discussed and manufacturing processes and cost structures analyzed. Polypeptide drug industry import/export consumption, supply and demand figures and cost price and production value gross margins are also provided. A key feature of the report is its focus on 20 industry players providing information such as products, customers, application, capacity, market position, company contact information and summary statistics. Upstream raw materials and equipment and downstream demand analysis is also carried out. Polypeptide drug industry development trends and marketing channels are analyzed. Finally the feasibility of new investment projects are assessed and overall research conclusions offered. Key Topics Covered - Synthesis Polypeptide Drug Industry Overview - Synthesis Polypeptide Drug International and China Market Analysis - Major Synthesis Polypeptide Drug Analysis - Synthesis Polypeptide Drug Industry Development Environmental Analysis - Synthesis Polypeptide Drug Development Policy and Plan - Synthesis Polypeptide Drug Manufacturing Process and Cost Structure - 2009-2014 Synthesis Polypeptide Drug Productions Supply Sales Demand Market Status and Forecast - Synthesis Polypeptide Drug Key Manufacturers - Up and Down Stream Industry Analysis and Influence - Synthesis Polypeptide Drug Marketing Channels Analysis - Synthesis Polypeptide Drug Industry Development Proposals - Synthesis Polypeptide Drug New Project Investment Feasibility Analysis - Synthesis Polypeptide Drug Industry Research Conclusions Companies Mentioned - Asahi Kasei - AstraZeneca - Beijing Shuanglu Pharmaceutical - Beijing Yingu Century Pharmaceutical (Beijing Shiqiao Bio-Pharmaceutical) - Changzhou Siyao Pharmaceutical - Chengdu Tiantaishan Pharmaceutical - Ferring Pharmaceuticals - HYBIO Pharmaceutical - Hainan Shuangcheng Pharmaceuticals - Hainan Zhonghe Pharmaceutical - Ipsen PHarma Biotech - Lilly - Livzon Pharmaceuticals - Merck Serono - Novartis - SciClone Pharmaceuticals - Sichuan Chengdu Diao Pharmaceutical Group - Takeda - Wuhan Hualong Bio-Chemical Pharmaceutical - Yangzijiang Pharmaceutica For more information visit http://www.researchandmarkets.com/research/k4ccf3/global_and About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Don Kan Filling Station Rejects Government's 'Cheaters' Label
by Henry Karmo - All Africa Global Media - Wed Jan 15, 9:31AM CST
The management of Don Kan Filling Station in Liberia has described as false and misleading, unfounded in a sharp response to the cheater label by the Ministry of Commerce against the company. Don Kan in a statement, also accused the Ministry of Commerce of witch hunting.
4 Stocks Under $10 Moving Higher
at The Street - Wed Jan 15, 6:00AM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
IPVanish VPN Partners With Lag Assassin -- Game Online With Assassin Speed
GlobeNewswire - Tue Jan 14, 8:43AM CST
IPVanish VPN, the world's leading provider of premium, high-performance VPN service, is thrilled to announce its latest partnership with exciting new service - Lag Assassin. Lag Assassin is powered by the Highwinds Game Delivery Network (GDN) and is new on the market as of just last week! While IPVanish secures Internet traffic, Lag Assassin gives online gamers a competitive edge with better ping time no matter what game they're playing. It does this by avoiding the unnecessary traffic paths an ISP takes while running in the background during game play.
SciClone Provides 2013 Financial Update and 2014 Guidance
Marketwire - Thu Jan 09, 5:00AM CST
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced its anticipated year-end 2013 cash position and provided its initial 2014 revenue guidance as follows.
SciClone to Present at Oppenheimer Healthcare Conference on December 10, 2013
Marketwire - Mon Dec 02, 5:00AM CST
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Friedhelm Blobel, Ph.D., Chief Executive Officer, will present a corporate overview and business update at the Oppenheimer 24th Annual Healthcare Conference on Tuesday, December 10, 2013, at 3:20 pm ET at the Crowne Plaza Hotel in New York.
(0)
(0)SciClone Pharmaceuticals Inc. (SCLN) Stock Research Links
Scroll down for more posts ▼